The next significant catalyst is MAIA-ovarian interim PFS data in Q1 2027. With ample cash runway, no near-term dilution expected despite $100M ATM remaining. Monitor enrollment updates and any pipeline expansion announcements. The stock may drift with broader biotech sentiment until data readout.
Drug in focus
CGEN drug pipeline →COM701
◆ Mixed Named in this 6-K- Impact
- Phase
- Phase 1/2
- Time to market
- At least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.
- Next catalyst
- None dated
What to watchThe next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027, roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 3 $2.38entry
- T+1 · 4mo ago 0.00%α −1.80% · $2.38
- T+5 · 3mo ago −1.68%α −3.71% · $2.34
- T+20 · 3mo ago +7.56%α +6.33% · $2.56
- T+60 · 21d ago −18.70%α −20.48% · $1.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (H1) driven by Gilead license recognition, while net loss remained flat at ~$14.7M. Pipeline milestones unchanged: MAIA-ovarian PFS data expected Q1 2027, rilvegostomig OS data presented at ASCO, and GS-0321 Phase 1 on track. Cash position of $125.3M with no debt provides runway into 2029, reducing near-term financing risk.
Key Facts
- Cash and marketable securities of $125.3M as of June 30, 2026, with no debt and runway into 2029
- MAIA-ovarian interim PFS analysis for COM701 expected by Q1 2027
- Rilvegostomig (AZ-partnered) showed first OS readout: median 16.8 months in 1L biliary tract cancer
- GS-0321 (Gilead-partnered) Phase 1 dose-escalation continuing as planned
- H1 2026 revenue $4.8M (+35% YoY), net loss $14.7M (flat YoY), cash used in ops $21.9M
Financial Impact
Revenue growth to $4.8M from $3.5M driven by Gilead license revenue; net loss stable at $14.7M; cash position $125.3M down from $145.6M at year-end 2025
Risk Factors
- MAIA-ovarian trial failure or delayed data readout
- Potential dilution from $100M ATM facility if cash burn accelerates
- Reliance on partnered programs (AstraZeneca, Gilead) for future milestones
- Israel geopolitical risk to operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003754 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-003754 |
| Exhibit: exhibit_99-3.htm | 0001178913-26-003754 |
| Document: zk2635762.htm | 0001178913-26-003754 |
| Document: 0001178913-26-003754-index-headers.html | 0001178913-26-003754 |
| Document: 0001178913-26-003754-index.html | 0001178913-26-003754 |
| Document: 0001178913-26-003754.txt | 0001178913-26-003754 |
Track record
9 reports on CGEN
Filters
- Nov 9, 20267d ago 6-K Neutral 4/10 Entry $2.14 Now $2.04 −4.67% settles Dec 8
- Aug 3, 202615w ago 6-K Neutral 2/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Aug 3, 202615w ago 6-K Neutral 4/10 Viewing Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Jun 9, 202623w ago EFFECT Neutral 3/10 Entry $2.02 to $2.39 Now $2.04 +0.99% ▲ +18.32% +16.87% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $2.86 to $2.03 Now $2.04 −28.67% ▼ −29.02% −30.60% vs SPY
- Apr 24, 202629w ago Insider Cluster Neutral 2/10 Entry $3.10 to $2.61 Now $2.04 −34.19% ▼ −15.81% −19.83% vs SPY
- Apr 14, 202631w ago Insider Cluster Neutral 2/10 Entry $2.88 to $2.87 Now $2.04 −29.17% ▼ −0.35% −6.64% vs SPY
- Apr 13, 202631w ago 144 Neutral 3/10 Entry $2.76 to $2.87 Now $2.04 −26.09% ▲ +3.99% −3.74% vs SPY
- Mar 26, 202633w ago Insider Cluster Neutral 3/10 Entry $2.06 to $3.10 Now $2.04 −0.97% ▲ +50.49% +39.82% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers